Recent perspectives into biochemistry of decavanadate

Table 1 Decavanadate in vivo studies in 2001-2010

Tissue	Effects	Administration mode	Exposition time	Ref.
H	Antioxidant enzymes	ip	1, 7 d	[7]
H/K/L	Histological effects	ip	1, 7 d	[8]
L	Vanadium accumulation	iv	12, 24 h, 7 d	[9]
	Antioxidant enzymes
H/B	Vanadium accumulation	iv	1, 6, 12 h	[10]
H	Lipid peroxidation	iv	1, 6, 12 h	[11]
	Antioxidant enzymes
H	Vanadium accumulation	iv	1, 7 d	[12]1
	Antioxidant enzymes

¹Comparison between vanadium (decavanadate, vanadate) and cadmium (5 mmol/L) administration. H: Heart; K: Kidney; L: Liver; B: Blood.

Table 2 Decavanadate in vitro studies in 2001-2010

Protein/effect	Vanadate species	Yr	Ref.
DNA-binding protein	V10	2002	[70]
Methemoglobin reductase inhibition	V10	2003	[73]
Actomyosin ATPase inhibition	V10	2004	[20]
Muscle contraction regulation	V10	2004	[21]
ATP sensitive cation -channel	V10	2004	[76]
TRPM4 cation channels	V10	2004	[71]
G-Actin polymerization inhibitor	V10, V4	2006	[36]
RNA triphosphatase	V10	2006	[72]
P2X receptor antagonist	V10	2006	[74]
Insulin mimetics	V10 compounds	2007	[57]
Back-door binding to myosin	V10	2007	[22]
Porin (VDC) modulator	V10	2007	[75]
Mitochondrial membrane depolarization	V10, V1	2007	[54]
Mitochondrial oxygen consumption	V10, V1	2007	[55]
Extracellular matrix mineralization	V10, V1	2008	[77]
Cardiomyocytes necrotic cell death	V10, V1	2008	[78]
Gelatine-mixtures	V10	2008	[79]
Adipocytes glucose accumulation	V10	2009	[68]
Actin oxidation and vanadyl formation	V10	2009	[52]
Anticancer activity	V10 compounds	2009	[58]
ATPase activity in synaptic membranes	V10	2009	[80]
Membrane models interaction	V10	2009	[81]
DNA cleavage	V10	2010	[82]
Actin structure and function	V10	2010	[2]
Anticancer activity	V10 compounds	2010	[59]

TRPM4: Transient receptor potential cation channel subfamily M member 4.